If either the angina or the hypertension remains un- controlled, a long-acting dihydropyridine CCB can be added to the basic regimen of -blocker, ACE inhibitor, and thiazide or thiazide-like diuretic. The combination of a -blocker and either of the nondihydropyridine CCBs (diltiazem or verapamil) should be used with cau- tion in patients with symptomatic CAD and hyperten- sion because of the increased risk of significant brady- arrhythmias and HF (Class IIa; Level of Evidence B). 5. For patients with stable angina, the BP target is <140/90 mmHg. (Class I; Level of Evidence A). See also the previous section BP and Treatment Goals. However, a lower target BP (<130/80 mmHg) may be considered in some individuals with CAD, with previ- ous stroke or transient ischemic attack, or with CAD risk equivalents (carotid artery disease, PAD, abdomi- nal aortic aneurysm) (Class IIb; Level of Evidence B). 6. There are no special contraindications in hyperten- sive patients for the use of antiplatelet or anticoagu- lant drugs, except that in patients with uncontrolled severe hypertension who are taking antiplatelet or anticoagulant drugs, the BP should be lowered with- out delay to reduce the risk of hemorrhagic stroke (Class IIa; Level of Evidence C). 5. Management of Hypertension in Patients With ACS Although a major risk factor for CVD, the impact of hyper- tension on ACS outcomes has not been well described. Few data are available on specific treatments for hypertension in patients with either STEMI or non ST-segment elevation ACS, including both UA and NSTEMI. 5.1. 